Dexcom (DXCM) Q4 2025 earnings summary

Executive summary

• Q4 2025 revenue reached $1.26 billion, up 13% year-over-year, driven by strong new customer demand and the successful G7 15-Day product launch in the U.S.

• CEO outlined strategic priorities: premier glucose sensing, customer experience excellence, and international market expansion.

• Significant operational improvements in manufacturing and logistics led to higher inventory and improved gross margin.

• International business showed robust growth, with France and other markets benefiting from expanded Type 2 access.

• FDA clearance received for Dexcom Smart Basal insulin optimizer, with early access launch in Q1 2026.

Financial highlights

• Q4 2025 worldwide revenue was $1.26 billion, up from $1.11 billion in Q4 2024 (13% growth).

• U.S. revenue grew 11% to $892 million; international revenue rose 18% to $368 million.

• Gross profit was $799.8 million (63.5% margin), up from 59.4% in Q4 2024.

• Operating income was $331.5 million (26.3% margin), and adjusted EBITDA was $422.2 million (33.5% margin).

• Net income for Q4 was $267.3 million, or $0.68 per share.

Outlook and guidance

• 2026 revenue guidance: $5.16–$5.25 billion, representing 11–13% growth.

• Full-year non-GAAP gross margin expected at 63–64%, operating margin at 22–23%, and adjusted EBITDA margin at 30–31%.

• Guidance assumes stable coverage, incremental growth from Stelo and new products, and margin improvement of 200–300 basis points.

• Investments planned for sales, innovation, and Ireland manufacturing facility launch in late 2026.

• Margin expansion driven by improved freight, manufacturing efficiencies, and G7 15-Day contribution.